Specify a stock or a cryptocurrency in the search bar to get a summary
Cingulate Inc
CINGCingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas. Address: 1901 West 47th Place, Kansas City, KS, United States, 66205
Analytics
WallStreet Target Price
80.33 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CING
Dividend Analytics CING
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CING
Stock Valuation CING
Financials CING
Results | 2019 | Dynamics |